Real-world treatment and utilization of venetoclax for incident acute myeloid leukemia in a Medicare population
Open Access
- 3 December 2025
- journal article
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (29) , 3811-3820
Abstract
This study aimed to describe first-line venetoclax in the Medicare population and its impacts on treatment patterns, utilization, and costs. This retrospective cohort study used Medicare Fee-For-Service data from 1 September 2016, to 31 December 2022. Patients were continuously-enrolled, had incident acute myeloid leukemia (AML) and no confounding diagnoses, and were treated with first-line venetoclax-based regimens. Initiation of second line of therapy was modeled using cumulative incidence functions. Among 2,765 included patients, median age was 76 years. Median venetoclax dosage was 140.4 mg/day - lower than the 400-600 mg/day recommended by clinical guidelines. Patients were less likely to initiate second-line therapy if they were older or had more comorbidities.Patients had a per-month median of 5.3 outpatient visits, 0.3 emergency department visits, and 0.2 hospitalizations; length of stay was 10 days. Mean monthly healthcare costs were $18,092 (SD=$14,289) per patient, with $12,042 (SD=$12,147) and $6,050 (SD=$7,841) attributable to medical services and drug costs, respectively. A growing number of patients enrolled in Medicare Fee-For-Service with AML use first-line venetoclax. Older patients and those with comorbidities are less likely to initiate second-line therapy. Costs were lower and length of stay was shorter than described in previous research.Keywords
Funding Information
- Pfizer
This publication has 28 references indexed in Scilit:
- Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patientsBlood Cancer Journal, 2025
- Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015–2020Leukemia & Lymphoma, 2021
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaNew England Journal of Medicine, 2020
- Management of Acute Myeloid Leukemia (AML) in Older PatientsCurrent Oncology Reports, 2020
- Treatment of Relapsed Acute Myeloid LeukemiaCurrent Treatment Options in Oncology, 2020
- Myelodysplastic Syndromes and Acute Myeloid Leukemia in the ElderlyClinics in Geriatric Medicine, 2016
- Acute Myeloid LeukemiaNew England Journal of Medicine, 2015
- Medicare Fee-for-Service Enrollees with Primary Acute Myeloid Leukemia: An Analysis of Treatment Patterns, Survival, and Healthcare Resource Utilization and CostsApplied Health Economics and Health Policy, 2013
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987